Acorda Therapeutics reportedly exploring potential sale

Finance


Acorda Therapeutics is exploring a sale of the company, the Wall Street Journal reported, citing people familiar with the matter.

Shares of the company closed up nearly 12 percent at $23.55 on Friday.

The Ardsley, New York-based company, which has a market value of about $980 million, may not move forward with any formal action as the proceedings were at an early stage, the WSJ report said.

Acorda was not immediately available for comment.

The U.S. drugmaker’s investors in August had called for the company to explore a sale, after a judge in March struck down key patents of its MS drug Ampyra, which accounts for most of its revenue.

The company also recently discontinued the development of its Parkinson’s drug after reports of death.

Read the full report in The Wall Street Journal.



Source link

Products You May Like

Articles You May Like

Deutsche Bank warns Netflix may miss second-quarter subscriber expectations
Goldman Sachs earnings Q2 2018
Jack Dorsey loses 200,000 followers on Twitter after fake user purge
Pricing for passengers starts after first crewed flights
PNC shares gain after higher commercial lending leads to better-than-expected earnings report

Leave a Reply

Your email address will not be published. Required fields are marked *